Insight Molecular Diagnostics Inc. (IMDX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IMDX Revenue Growth
Revenue Breakdown (FY 2024)
IMDX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
IMDX Revenue Analysis (2013–2024)
As of May 8, 2026, Insight Molecular Diagnostics Inc. (IMDX) generated trailing twelve-month (TTM) revenue of $4.4 million, reflecting explosive growth of +126.1% year-over-year. The most recent quarter (Q3 2025) recorded $260,000 in revenue, down 49.8% sequentially.
Looking at the longer-term picture, IMDX's historical revenue data shows a 3-year CAGR of -5.1%. The company achieved its highest annual revenue of $2.2 million in 2021.
Revenue diversification analysis shows IMDX's business is primarily driven by Pharma Services (100%). With over half of revenue concentrated in Pharma Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NTRA (+35.9% YoY), EXAS (+17.7% YoY), and CDNA (+19.2% YoY), IMDX has outperformed the peer group in terms of revenue growth. Compare IMDX vs NTRA →
IMDX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IMDXCurrent | $4M | +126.1% | - | -3245.1% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% |
IMDX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.9M | +25.1% | $740K | 39.3% | $-61,041,000 | -3245.1% |
| 2023 | $1.5M | +56.9% | $413K | 27.5% | $-25,136,000 | -1672.4% |
| 2022 | $958K | -56.4% | $-18,000 | -1.9% | $-17,997,000 | -1878.6% |
| 2021 | $2.2M | +80.8% | $1.4M | 64.6% | $-53,725,000 | -2444.3% |
| 2020 | $1.2M | - | $-639,000 | -52.5% | $-29,711,000 | -2443.3% |
| 2019 | $0 | - | $-344,000 | - | $-22,239,000 | - |
| 2018 | $0 | - | $-559,000 | - | $-15,202,000 | - |
| 2017 | $0 | - | $-580,000 | - | $-18,849,000 | - |
| 2016 | $0 | - | $-387,000 | - | $-11,140,000 | - |
| 2015 | $0 | - | $-283,000 | - | $-8,718,000 | - |
See IMDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIMDX — Frequently Asked Questions
Quick answers to the most common questions about buying IMDX stock.
Is IMDX's revenue growth accelerating or slowing?
IMDX revenue is accelerating at +126.1% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $4M. Growth momentum has increased versus prior periods.
What is IMDX's long-term revenue growth rate?
Insight Molecular Diagnostics Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +126.1% is above this long-term average.
How is IMDX's revenue distributed by segment?
IMDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.